A History of Successful Clinical Trials

Seeking New Clinical Trials
GW Research has performed clinical trials since our start in 1999. We have performed over 25 clinical trials in phase II, III and IV, in collaboration with multiple sponsors. We have always been attentive to our relationship with the sponsors and clinical research organizations. Since we have a limited bureaucratic structure, one on one communication with CRC, SI and PI have always been encouraged and performed. Most of the studies this organization has performed are in Gastroenterology and Internal Medicine.

Clinical Trials: Investigator Participation

  1. A Randomized Study of Oral Lobucavir vs. Alpha Interferon in Subjects Chronically Infected with Hepatitis B Virus. June 1998- April 1999. (1 patient enrolled, Sponsor canceled study).

  2. A Multicenter, Randomized, Double-Blind, Safety, and Efficacy Study of H 199/18 for the Eradication of Helicobacter pylori in Subjects with Active Duodenal Ulcer or History of Duodenal Ulcer Disease. October 1998- April-1999. (Three patients enrolled and screened)

  3. A twelve-week randomized, double-blinded, placebo-controlled study of the efficacy and tolerability of Aloseteron Hydrochloride 1mg twice daily for control of bowel urgency in patients with diarrhea-predominant irritable bowel syndrome. Protocol: s3b30011 (1999-2000) (8 screened and 2 enrolled)

  4. Aciphex Post Marketing Fast Trial. (10 patients enrolled and screened) (2000)

  5. A Comparative Efficacy Study of esomeprazole Magnesium 40mg and Lansoprazole 30mg in patients with erosive esophagitis. (Protocol 267) September 2000- December 2000. (32 patients enrolled and 5 screen failures).

  6. A Double-Blinded, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of 2 mg TID of Cilansetron Over 12 Weeks Followed by a 4-week re-randomized treatment of period in diarrhea-predominant Irritable Bowel Syndrome Subjects. (12 enrolled, 4 screens failed)

  7. A Randomized Double-Blind Trial Comparing the Early Profile of Heartburn Relief Associated with Rabeprazole, 20 mg Once Daily vs. Omeprazole, 20mg Once Daily in Gastroesophageal Reflux Disease Patients with an Acute or Documented History of Erosive Esophagitis. (23 enrolled, 4 screen failures)

  8. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of repeated treatment with tegaserod 6 mg BID and placebo in female patients with irritable bowel syndrome with constipation (IBS-C) (20 patients enrolled and 23 patients screened)

  9. A Twelve-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5mg QD, 1mg QD and 1mg BID of Alosetron in Female Subject with Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy

  10. Dx-1 Non Invasive pH Measurement Device Study. Sept 2004-Oct 2005

  11. A 12-Week Multi-center, Double-Blind, Randomized Efficacy and Safety Study of Lubiprostone for the treatment of Constipation Predominant Irritable Bowel Syndrome (PRA International Trial)

  12. A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR – Studies T-EE04-084, TGD-04082, T-EE04-086, T-GI04-088, TGI05-137, TEE05-135 (6 STUDIES- 48 patients enrolled, 25 screen failures) Nov.2005-2006

  13. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Renzapride in Women with Constipation Predominant Irritable Bowel Syndrome. June 2007

  14. Gastrointestinal (GI) Randomized event and safety Open-Label NSAID Study (GI-REASONS): A Randomized Open-Label, Blinded Endpoint, Parallel-Group Trial of GI Safety of Celecoxib Compared with Non-Selective Nonsteroidal

  15. Anti-inflammatory 22 Drugs (NSAIDS) in Osteoarthritis Patience Protocol A3191331. Jan. 2007-2008.

  16. Multicenter, randomized, placebo-controlled, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in patients with Opioid-induced Bowel Dysfunction.2008.

  17. A Multicenter, randomized, placebo-controlled, double-blinded study on the efficacy and safety of SPI-8811 for the prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in patients with osteoarthritis and/or rheumatoid arthritis. 2-12/2008.

  18. A Randomized Double-Blind parallel study of Rabeprazole Extended release 50mg versus Esomeprazole 40 mg for healing and symptomatic relief of mild to moderate erosive gastroesophageal reflux disease (GERD). 7/2008 -6/2009 (30 screened/9 randomized)

  19. A Randomized Double-Blind parallel study of Rabeprazole Extended-release 50mg versus Esomeprazole 40 mg for healing and symptomatic relief of moderate to severe erosive gastroesophageal reflux disease (GERD). 3/2008 -6/2009 (20 screened/10 randomized)

  20. A Randomized Double-Blind parallel study and of Rabeprazole Extended-release 50mg versus Esomeprazole 40 mg for maintenance of erosive gastroesophageal reflux disease (GERD). 3/2008 -6/2009 (7 screened/7 randomized)

  21. A Phase 3, Randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin 550 mg TID in the treatment of subjects with non–constipation irritable bowel syndrome. 11/08 -4/2009 (5 screened/4randomized)

  22. A phase 3, randomized double-blind, placebo-controlled, parallel-group trial of linaclotide administered orally for 12 weeks followed by a 4-week randomized withdrawal period in patients with chronic constipation. 1/09 (8 screened/1 Randomized)

  23. An Open-label, Long-term Safety Study of Oral Linaclotide Administered to patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation. 1/09 – 09/2011 (6 screened/4 randomized)

  24. A Phase III, Randomized, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis 2009-04/2012 (11 screened/8 randomized)

  25. A phase 3, randomized double-blind, placebo-controlled, parallel-group trial of linaclotide administered orally for 26 weeks with Irritable Bowel Syndrome with constipation. 9/2009 (17 screened/1 randomized)

  26. A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS). 9/2010 – 3/2013 (39 screened/9 randomized.

  27. A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers April 2010 – 03/2012 (17 screened/9 randomized)

  28. A Phase 3, Randomized, double blind placebo controlled multicenter study to assess the efficacy and safety of budesonide foam ( 2mg/25ml bid for 2 weeks, followed by 2mg/25 ml qd for 4 weeks) versus placebo in subjects with active mild to moderate ulcerative proctitis or proctosigmoidits: August 2010- June 2013(9 screened/3Randomized)

  29. A Phase 3, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects with

  30. Active Ulcerative Proctitis or Proctosigmoiditis: September 2011 – September 2013(1 randomized)

  31. A Phase 2b Randomized, Double-Blind, Placebo-Controlled, 28-Day Repeat, Oral, Dose-Ranging Study to Assess the Safety and Pharmacodynamic Effects of SP-304 in Patients with Chronic Idiopathic Constipation: October 2011 –February 2013 (40 screened/20 randomized)

  32. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-27018966 in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome: May 2012 – February 2014(14 screened/ 7 randomized)

  33. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-27018966 in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome – Open Label: June 2013 – February 2014 (3 screened/ 2 randomized)

  34. A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D): June 2012 – June 2014 (34 screened/17 enrolled)

  35. A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): November 2012-ongoing (14 screened/2 randomized)

  36. A Phase 3, Double-Blind, Multi-Center, Placebo-Controlled Maintenance Trial Designed to Evaluate the Efficacy and Safety of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy: March 2013-November 2014 ( 8 screened/4 randomized )

  37. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults taking Opioid Therapy for Chronic Non-Cancer Pain: May 2013 – September 2013 ( 3 screened/2 randomized)

  38. A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5mg and 10mg for 26 weeks: July 2013 – June 2014 ( 15 screened/3 randomized)

  39. A Multi-Center, Open-Label, Safety and Tolerability Extension Trial of 5mg and 10g Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation: March 2014 – March 2014(3 randomized)

  40. A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose. Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): December 2012 – May 2014 ( 39 screened/10 randomized)

  41. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects with Early Decompensated Liver Cirrhosis: September 2013 – ongoing (20 screened/10 randomized)

  42. A Randomized, 12 Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0) in Patients with Chronic Idiopathic Constipation (CIC3). November 2013 – ongoing (55 screened/26 randomized to date)

  43. An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC).September 2013 – ongoing (23 rollover)

  44. A 12-week double-blind, randomized, placebo-controlled, parallel-group phase III study, followed by a 4-week randomized withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhea (IBS-D). Study Code: NAK-06; Study Acronym: IRIS-3: Ibodutant for Relief of Irritable Bowel Syndrome: March 2014 – ongoing (6 screened/1 randomized to date) NCT02107196

  45. A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis.August2014-October 2014 (12 screened)

  46. (Ironwood Gastroparesis) ICP-112-202; A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients with Diabetic Gastroparesis. November2014 – ongoing (63screened/12 randomized)

  47. A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients with Irritable Bowel Syndrome with Constipation (IBS-C). December 2014 – July 2015 (9 screened/4 randomized)

  48. (Sucampo IBS-M/IBS-U) A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Lubiprostone in Adult Subjects With Mixed or Unsubtyped Irritable Bowel Syndrome (IBS-M/IBS-U) February 2015 – ongoing NCT02544152

  49. (Ironwood IBS-C) A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) February 2015 – July 2015 ( 9 screened/4 randomized) D5630C00001

  50. (Ironwood CIC) A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation February 2015- October – 2015 ( 32 screened/18 randomized) (CIC) NCT02291679

  51. (Shire EOE) Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study November 2015 – ongoing (EOE) NCT0260583

  52. Ardelyx Pharmaceuticals, A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C) October 2015 – October 2016 (14 screened/ 4 randomized) NCT02621892.

  53. Allergan Pharmaceuticals, Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms with Prior Loperamide Use. January 2017 – ongoing. (8 screened / 4 randomized)

  54. Intercept Pharmaceuticals, Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatis. December 2016 – ongoing (19 screened / 5 randomized) NCT02548351

  55. Octeta Therapeutics, Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients with NASH. December 2016 – ongoing. (4 screened/1 randomized) NCT02784444

  56. Genfit Pharmaceuticals, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis. November 2016 – ongoing (2 screened) NCT02704403

  57. Theravance Pharmaceuticals, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety and Tolerability of Velusetrag for the Treatment of Diabetic and Idiopathic Gastroparesis. September 2016 – ongoing. (24 screened/ 11 randomized) NCT02267525

  58. SERES Therapeutics, Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study Designed to Evaluate the Safety and Tolerability of SER-287, and to Evaluate the Microbiome Alterations and Pharmacodynamics Associated with 2 Dosing Regimens of SER-287 in Adults Subjects with Mild-to-Moderate Ulcerative Colitis. September 2016 – ongoing. (3 screened/ 3 randomized) NCT02618187

  59. Synergy Therapeutics, A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation. August 2016 – ongoing. (10 screened/ 8 randomized

  60. Ironwood Pharmaceuticals, A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients with Symptomatic GERD that Persists Despite Treatment with Proton Pump Inhibitors. March 2016 – ongoing. (28 screened/ 7 randomized) NCT02637557

  61. Ardelyx Pharmaceuticals, A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C) February 2016 – ongoing. (17 screened/ 10 randomized)

  62. Ferring Pharmaceuticals, Phase 3, Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution versus Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Powder for Oral Solution (PREPOPIK) for Colon Cleansing in Preparation for Colonoscopy. February 2017 – Ongoing. (101 Screened / 90 Randomized) one of top enrolling sites

  63. A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter pylori (H. pylori) Infection, RHB-105-02 July 2017 – December 2018 (49 Screened/20 Randomized) one of top enrolling sites

  64. A Safety and Efficacy Comparison of BLI4700 Bowel Preparationversus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy January 2018 – November 2018 (12 Screened/12 Randomized) one of top enrolling sites

  65. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis February 2018 – ongoing (6 Screened)

  66. RLM-MD-02: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis March 2018 – ongoing (23 Screened)

  67. RLM-MD-03: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis July 2018 – ongoing (3 randomized rollovers)

  68. RLM-MD-04: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis June 2018 – ongoing (10 screened)

  69. MCP-103-312: A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 µg Administered Orally for 12 Weeks in Patients with Irritable Bowel Syndrome with Constipation July 2018 – ongoing (30 screened/16 randomized)

  70. C3718-301: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors September 2018 – ongoing (13 screened)

  71. Protocol G28-006: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients with Lactose Intolerance August 2018 – ongoing (22 screened)

  72. 3152-301-002 – AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic November 2018 – ongoing (7 screened)

  73. VP-VLY-686-3301Vanda: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis November 2019 – ongoing (90 screened,)

  74. Phathom Pharmaceuticals, Inc. A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis November 2019 – ongoing (3 screened)

  75. 2018-10, An Evaluation of a Multi-target Stool DNA (mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now October 2019 – ongoing (47 screened)

  76. PBGD 1001, An Open-Label, Multicenter Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Patients with Functional Gastrointestinal Disturbances October 2019- December 2019 (20 screened / 20 randomized)

  77. Genentech, Inc. GC41033A Phase II, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of bfkb8488a compared with placebo in patients with non-alcoholic steatohepatitis, February 2019

  78. APD371202, A Phase 2, MultiCenter, Randomized, DoubleBlind, PlaceboControlled ParallelGroup Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain, February 2019

  79. Braintree Protocol BLI4900-302, A Safety and Efficacy Comparison of BLI4900 Bowel Preparation versus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy, February 2019

  80. Allakos, Inc., A Prospective Study to Identify the Incidence of Eosinophilic Gastrointestinal Diseases and Elevated Tissue Mast Cells among Patients with Chronic Gastrointestinal Symptoms, March 2019

  81. Exact Sciences Act Fast 2018-07, Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion, April 2019
    ​​​​​​​

  82. Exact Sciences Act Fast 2018-07: Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion. April 2019-ongoing (21 screened/enrolled)

  83. Phathom HP-301, A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole 30 mg Daily in Patients with Helicobacter Pylori Infection. October 2019- May 2021 (37 screened, 26 randomized)

  84. Allakos Study AK002-016: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) Who Have an Inadequate Response with, Lost response to, or Were Intolerant to Standard Therapies, December 2020- August 2023 (31 Screened, 8 Randomized)

  85. Exact Sciences, 2019-01: “Clinical Validation of an Optimized Multi-Target Stool DNA (mt-sDNA 2.0) TEST, for Colorectal Cancer Screening” February 2021- May 2023 (297 screened/ randomized)

  86. Neurogastrx NG101-201: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of NG101 Administered Orally to Patients with Gastroparesis. May 2021- April 2023 (27 screened, 3 randomized)

  87. Phathom NERD-201: A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg, 20 mg and 40 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease. March 2021- February 2022 (33 screened, 8 randomized)

  88. Allakos Study AK002-016X: A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That were Previously Enrolled in AK002-016 or AK002-012 studies and have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis). July 2021- September 2023 (8 screened/randomized)

  89. Allakos Study AK002-021: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Duodenitis who have an Inadequate Response with Lost Response to, or were Intolerant to Standard Therapies. July 2021- March 2023 (17 screened, 3 randomized)

  90. Ionis ION224-CS2: An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects with Confirmed Non-Alcoholic Steatohepatitis. (patient enrollment- 1.5 years) July 2022-July 2023 (15 screened, 2 randomized)

  91. Phathom NERD-301: A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg Compared to Placebo for Relief of Heartburn in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) After 4 Weeks and to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg for Relief of Heartburn in Subjects with NERD After 6 Months. February 2022- July 2023 (55 screened, 15 randomized)

  92. Exact Sciences 2021-02: Clinical Utility of Oncoguard Liver Test. February 2022- July 2022 closed by Sponsor (9 screened)

  93. Inventiva, 337HNAS20011: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis. (Patient enrollment time- 5 years) May 2022-ongoing (10 screened, 1 randomized)

  94. Citius, 143-11351-202: A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids. August 2022-July 2023 (6 screened, 3 randomized)

  95. ReStalsis, RF-001: ReStalsis Interferential Therapy (IFT) for the Treatment of Chronic Constipation. July 2022- August 2023 (8 screened, 3 randomized)

  96. Braintree BLI5100-301: A Phase 3, Double-Blind, Randomized, Two-Phase, Active Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients With Erosive Esophagitis. November 2022-ongoing (120 screened, 8 randomized)

  97. Braintree BLI5100-302: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients With Non-Erosive Reflux Disease. November 2022-ongoing (86 screened, 8 randomized)

  98. HighTide, HTD1801.PCT014 A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis who Have Type 2 Diabetes or Pre-Diabetes April 2023-ongoing (1 screened)

  99. Salix RNLC3131: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C). May 2023- ongoing (2 screened)

  100. Braintree BLI5100-303: A Phase 3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients With Gastroesophageal Reflux Disease August 2023- ongoing(4 screened, 4 randomized)

  101. Celldex, CDX0159-08: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The "EvolvE" Study) September 2023-ongoing (1 screened)

  102. Akero AK-US-001-0105: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis (Patient enrollment time- years) September 2023-ongoing
    ​​​​​​​

  103. Akero AK-US-001-0107: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Nonalcoholic Fatty Liver Disease (NAFLD) (Patient enrollment time- years) September 2023-ongoing

Quick Links

Volunteer Now

Learn More

Keep
In Touch

Contact Us
admin none 9:00 am-4:00 pm 9:00 am-4:00 pm 9:00 am-4:00 pm 9:00 am-4:00 pm 9:00 am-4:00 pm Closed Closed # # #